BioVectra

BioVectra is a contract development and manufacturing organization (CDMO) headquartered in Charlottetown, PE, Canada, with a long-standing reputation as a trusted partner for pharmaceutical and biotechnology companies requiring complex molecule manufacturing. Operating as a research laboratory in Charlottetown, BioVectra has built considerable credibility in the peptide and API industry by supporting both clinical-stage and commercial-scale projects with rigorous scientific expertise. Now operating under the Agilent Advanced Therapeutics umbrella following its acquisition by Agilent Technologies, BioVectra continues to serve the industry with the same commitment to quality and innovation that defined its independent operations.

As a full-service CDMO and research laboratory, BioVectra offers an extensive range of manufacturing and development services that span the drug development lifecycle. Their capabilities include the synthesis and production of highly potent APIs, peptide active pharmaceutical ingredients, biologics, synthetic small molecules, plasmid DNA, mRNA, lipid nanoparticles, guide RNA, bioreagents, fermented small molecules, and fill/finish services. Research labs operating at this level of technical complexity provide pharmaceutical partners with end-to-end project support, from early-stage research and development through to clinical and commercial manufacturing, making BioVectra a versatile resource for teams working with challenging molecular platforms.

BioVectra occupies a distinguished position among Canadian research labs, offering national reach across Canada while also serving international clients through its expanded capabilities under the Agilent Advanced Therapeutics network. As a research laboratory in Charlottetown that has grown to support some of the most demanding projects in the peptide and advanced therapeutics sector, BioVectra bridges the gap between scientific discovery and scalable manufacturing. Their national distribution capabilities make them an accessible and strategic partner for pharmaceutical developers, biotech companies, and clinical research organizations operating anywhere across Canada.

For industry professionals evaluating research labs for peptide API manufacturing or clinical trial support, quality systems and regulatory compliance are paramount considerations. BioVectra is ISO 9001 and GMP-certified, ensuring that manufacturing processes, documentation, and quality controls meet the expectations required for clinical and commercial pharmaceutical production. Organizations sourcing from research laboratory partners should look for demonstrated experience with complex and highly potent compounds, robust quality management infrastructure, and a track record of supporting projects through multiple phases of development — standards that BioVectra consistently upholds within its operations.

Industry professionals, researchers, and clinical development teams seeking a reliable CDMO partner for peptide APIs and advanced therapeutic manufacturing are encouraged to connect directly with BioVectra to discuss project needs, timelines, and technical capabilities. Whether your organization requires early-phase development support or large-scale commercial manufacturing, BioVectra's team in Charlottetown, PE stands ready to provide expert guidance. Reaching out to their project support team is the first step toward establishing a manufacturing partnership built on scientific excellence and compliance-driven quality.